Re Agreement

Alliance Pharma PLC
17 November 2004

For immediate release:  17th  November 2004





                              ALLIANCE PHARMA PLC

                         ('Alliance' or 'the Company')

             CO-PROMOTIONAL AGREEMENT WITH VALEANT PHARMACEUTICALS



Alliance Pharma plc, (LSE.APH) the Chippenham based emerging speciality
pharmaceutical company, today announced that it has signed an agreement with
Valeant Pharmaceuticals Ltd to co-promote SymmetrelTM (amantadine), Alliance's
treatment for Parkinson's disease alongside Valeant's MestinonTM
(pyridostigmine), for the treatment of myasthenia gravis, to hospital
neurologists.  The agreement will mean that both specialist sales forces will
promote the benefits of Symmetrel alongside Mestinon to hospital neurologists
and specialists involved in the care of the elderly.



The combined sales forces will now reach over 90% of UK neurologists with both
products, creating the second largest dedicated neurology sales force in the
country.  Alliance acquired the Symmetrel brand from Novartis in October 2001
and has grown the sales to its current level of £1.2m in the UK.  It is
specifically aimed at treating the dyskinesias (abnormal involuntary movements)
associated with Parkinson's disease which currently affects a growing population
of more than 15,000 patients in the UK alone.



John Dawson, CEO of Alliance Pharma commented:



'The agreement with Valeant confirms our position as a significant force in the
neurology sector and endorses our stated strategy of being the partner of choice
for commercialising products from emerging biotech and global R&D companies.



Co-promotion agreements of this nature create platforms from which we can
develop the sales potential within our existing range of 30 pharmaceutical
brands.  This success then provides an added advantage when competing for future
brands or in-licensing opportunities.'





                               -          ends -



For further information please contact:



Alliance Pharma plc
John Dawson
CEO
01249 466966



Beattie Financial
James Chandler/Mike Wort/John Moriarty
020 7398 3300


About Alliance Pharma


Alliance Pharma, founded in 1996, is an AIM listed emerging speciality
pharmaceutical company based in Chippenham, Wiltshire.  The company has a strong
track record of acquiring the rights to established niche brands and owns, or
shares, the rights to 30 branded pharmaceutical products and is currently
exploring several opportunities to expand the range.  In November 2003 the
company acquired Peerless Technology Group Plc constituting a reverse takeover
under the AIM rules.


Valeant Pharmaceuticals International (NYSE: VRX)  is a global, publicly traded,
research-based, specialty pharmaceutical company that discovers, develops,
manufactures and markets a broad range of pharmaceutical products. Valeant is
focused on marketing and distributing pharmaceuticals in the areas of neurology,
dermatology and infectious disease. They are distributed to hospitals directly
and to pharmaceutical wholesalers who service both hospital and retail
pharmacies with their prescription requirements.






                      This information is provided by RNS
            The company news service from the London Stock Exchange